Pharmaceuticals

GZBL

GZBL released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 644.12 M, actual EPS CNY 0.02

GZBL released FY2025 Annual Earnings on April 27 Pre-Market (BJT), Actual Revenue CNY 3.049 B (Forecast CNY 6.475 B), Actual EPS CNY -0.08 (Forecast CNY 0.49)

GZBL released FY2025 Q4 earnings on April 27 Pre-Market BJT, actual revenue CNY 947.05 M, actual EPS CNY -0.1683

GZBL to Release FY2026 Q1 Earnings on April 28 After-Market (BJT)

GZBL to Release FY2025 Earnings on April 24 Pre-Market (BJT), Forecast Revenue CNY 6.475 B, EPS CNY 0.49

GZBL released FY2025 Q3 earnings on October 24 During-Market (BJT), actual revenue CNY 639.6 M, actual EPS CNY 0.0029

GZBL released FY2025 9 Months Earnings on October 24 During-Market (BJT), actual revenue CNY 2.102 B, actual EPS CNY 0.0429

GZBL to Release FY2025 Q3 Earnings on October 25 During-Market (BJT)

GZBL released FY2025 Q2 earnings on August 19 During-Market (BJT), actual revenue CNY 701.39 M, actual EPS CNY 0.02

GZBL released FY2025 Semi-Annual earnings on August 19 During-Market BJT, actual revenue CNY 1.462 B, actual EPS CNY 0.04

GZBL to Release FY2025 Semi-Annual Earnings on August 20, 2025 (BJT)

Guiyang Bailin Removed Other Risk Warnings and Restored Normal Price Fluctuation Limits

GuiZhou Bailin Announces 2024 Annual Report and 2025 Q1 Report

Guizhou Bailin Publishes Research on Diabetic Foot Ulcers

ST Bailin's internal control issues resolved, applies to revoke risk warning

Guiyang Bailin Reports Profitable 2024 Annual Report

ST Bailin Sees Revenue and Net Profit Decline in Q1 2025

GZBL released FY2025 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 760.59 M, actual EPS CNY 0.02

GZBL released FY2024 earnings on April 28 After-Market (BJT), actual revenue CNY 3.825 B (forecast CNY 5.434 B), actual EPS CNY 0.02 (forecast CNY 0.33)

GZBL released FY2024 Q4 earnings on April 28 After-Market BJT, actual revenue CNY 1.05 B, actual EPS CNY -0.0235

003008

300091

300489

002424

Rokid founder Mingo Zhu stated that the company will proceed with its joint-stock reform at a normal pace and has abundant cash flow. Although there are reports that the company plans to submit a listing application to the Hong Kong Stock Exchange by the end of April, he did not respond to these rumors

Wallstreetcn

KETOP

Optics Tech

Rokid Founder Mingo Zhu Responds: Company Restructuring and Joint-Stock Reform Proceeding at Normal Pace

GZBL announced that the revenue for the third quarter was 640 million yuan, a year-on-year increase of 1.11%; the net profit was 4.9798 million yuan, a year-on-year increase of 559.90%. The revenue for the first three quarters was 2.102 billion yuan, a year-on-year decrease of 24.28%; the net profit was 56.8144 million yuan, a year-on-year decrease of 35.60%

Zhitong

GZBL: Net profit for the third quarter was 4.9798 million yuan, a year-on-year increase of 559.90%

002793

The concept of innovative drugs continues the rebound momentum from yesterday, with GZBL and Luoxin Pharmaceutical hitting the daily limit, Sanofi's stock rising over 10%, and Laimei Pharmaceutical, Hainan Haiyao, Guangshengtang, and Yifang Biotechnology also following suit

Luoxin Pharmaceutical

The concept of innovative drugs continues to rebound, with GZBL and Luoxin Pharmaceutical both hitting the daily limit

The traditional Chinese medicine sector experienced a volatile rise, with GZBL hitting the limit up, and Weikang Pharmaceutical, Darentang, Fangsheng Pharmaceutical, Panlong Pharmaceutical, and Wohua Pharmaceutical following suit. In terms of related ETFs, the traditional Chinese medicine ETF had a transaction volume of 15.1552 million yuan. On October 15th, GZBL announced that its subsidiary "Bailing Yuxiu Pharmaceutical Co., Ltd." has once again received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration's Drug Evaluation Center, allowing the clinical trial of the traditional Chinese medicine Class 1 new drug Tangning Tongluo Tablets for the treatment of Type 2 diabetes

The traditional Chinese medicine sector fluctuated and surged, with GZBL hitting the limit up

According to the Zhitong Finance APP, GZBL announced that its wholly-owned subsidiary Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. (referred to as "Bailing Yuxiu") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The clinical trial application for Tangning Tongluo tablets submitted by Bailing Yuxiu has been approved, allowing the product to conduct clinical trials for Type 2 diabetes

GZBL: The clinical trial application for Tangning Tongluo tablets has been approved

GZBL announced in its 2025 semi-annual report that its capacity expansion and technological transformation project has been completed and put into production, increasing the pre-processing capacity of traditional Chinese medicinal materials from 25,000 tons/year to 60,000 tons/year, enhancing the industry's scale advantage. The company has established business relationships with over 80% of end customers nationwide, with more than 600,000 end customers and over 100,000 signed VIP customers

GZBL: The capacity expansion and technological transformation project has been completed and put into production, increasing the processing capacity of traditional Chinese medicinal materials to 60,000 tons per year

GZBL announced that in the first half of 2025, operating revenue was 1.462 billion yuan, a year-on-year decrease of 31.77%. Net profit was 51.8346 million yuan, a year-on-year decrease of 40.73%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

GZBL: Net profit of 51.8346 million yuan in the first half of 2025, a year-on-year decrease of 40.73%

688321

300204

002940

600521

603716

36Kr learned that, as of the time of publication, the innovative drug concept has been repeatedly active, Staidson BioPharm has reached a new historical high, Thalys has had two consecutive limit-ups, Chipscreen has risen over 10%, and ALK, GZBL, and huahaipharm have also seen significant increases

36Kr

Chipscreen

Staidson BioPharm

huahaipharm

Thalys

The innovative drug concept is repeatedly active, and Staidson BioPharm has reached a new historical high

688658

603936

300723

GZBL, Shandong Glass Fiber, and BOMIN ELECTRONICS hit the daily limit, ApicHope and YKYY rose over 10%; pharmaceutical stocks surged across the board, fiberglass and PCB concepts strengthened, while stablecoins and cultural media saw significant declines; the Shanghai Composite Index rose 0.39%, the Shenzhen Component Index rose 0.11%, and the ChiNext Index fell 0.24%

YKYY

BOMIN ELECTRONICS

ApicHope

ChiNext

The three major A-share indices closed mixed

According to the Zhitong Finance APP, ST GZBL announced that the company's stock will be suspended for trading for one day on June 27, 2025, and will resume trading on June 30, 2025. Starting from the market opening on June 30, 2025, the other risk warnings for the company's stock will be lifted, and the stock abbreviation will change from "ST GZBL" to "Guizhou GZBL," while the stock code will remain "002424." After the removal of other risk warnings, the daily price fluctuation limit for the company's stock will change from 5% to 10%

ST GZBL stock cancels other risk warnings and will be suspended for 1 day on June 27

GZBL(002424.SZ)